Appendix 4D & Half Yearly Report and Accounts
Filed with ASX · · 19 pages · English
PharmAust Limited - Consolidated Refer to Directors’ Report included in the attached half-year financial report. Dividends No Dividends were paid or declared for payment during the half-year period under review. Earnings Per Share Net Tangible Asset Backing Entities Acquired and Disposed During the Period There were no entities acquired or disposed of during the period. Compliance Statement The re
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Notice of Allowance received from USA Patent OffIce
- Treatment of Canine Cancers
- SPP Shortfall Heaily Oversubscribed
- Share Sale Deed executed for the sale of Pela Resources
- Shareholder Update - Human & Canine Trials
Later from Neurizon Therapeutics
- Strategy for Phase II Clinical Trial of Monepantel
- Appendix 4C Quarterly & Company Update
- Clinical Trial in Dogs is now open for accrual
- Human Cancer Trial Advancing To Second Patient
- Appendix 4C
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics